Rockefeller Capital Management L.P. Acquires 185,684 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Rockefeller Capital Management L.P. grew its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 19.5% in the 3rd quarter, Holdings Channel reports. The firm owned 1,139,934 shares of the biopharmaceutical company’s stock after acquiring an additional 185,684 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in ACADIA Pharmaceuticals were worth $17,532,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Stonepine Capital Management LLC raised its holdings in ACADIA Pharmaceuticals by 3,837.9% during the 3rd quarter. Stonepine Capital Management LLC now owns 196,895 shares of the biopharmaceutical company’s stock worth $3,028,000 after purchasing an additional 191,895 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in ACADIA Pharmaceuticals by 259.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock worth $3,439,000 after purchasing an additional 161,331 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in ACADIA Pharmaceuticals during the 3rd quarter worth approximately $342,000. Fisher Asset Management LLC raised its holdings in ACADIA Pharmaceuticals by 19.7% during the 3rd quarter. Fisher Asset Management LLC now owns 194,599 shares of the biopharmaceutical company’s stock worth $2,993,000 after purchasing an additional 31,980 shares during the last quarter. Finally, Algert Global LLC raised its holdings in ACADIA Pharmaceuticals by 2.9% during the 3rd quarter. Algert Global LLC now owns 549,456 shares of the biopharmaceutical company’s stock worth $8,451,000 after purchasing an additional 15,313 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ACAD shares. Royal Bank of Canada lowered their price target on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Cantor Fitzgerald lowered their price objective on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Raymond James reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. StockNews.com lowered shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $25.56.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,073 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $68,467.13. Following the transaction, the insider now directly owns 19,863 shares of the company’s stock, valued at $333,897.03. The trade was a 17.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark C. Schneyer sold 10,259 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the transaction, the chief financial officer now directly owns 53,302 shares in the company, valued at $896,006.62. This represents a 16.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,661 shares of company stock valued at $414,551 in the last three months. 28.30% of the stock is currently owned by insiders.

ACADIA Pharmaceuticals Trading Up 0.2 %

NASDAQ ACAD opened at $16.32 on Monday. The company has a market cap of $2.72 billion, a P/E ratio of 20.92 and a beta of 0.38. The company has a fifty day simple moving average of $15.61 and a 200 day simple moving average of $16.01. ACADIA Pharmaceuticals Inc. has a 12-month low of $14.15 and a 12-month high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.06. The firm had revenue of $250.40 million for the quarter, compared to the consensus estimate of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The business’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.40) EPS. Sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.73 EPS for the current year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.